干细胞来源配子:临床引入时可预期什么
本文为小型综述,概述由诱导多能干细胞或自体细胞来源的人配子(iPSCD-gametes)在临床试验前、中、后三个阶段面临的议题。作者指出,负责任地实现人iPSCD-gametes的临床引入可能比预期耗时更长,强调需要与广泛利益相关方开展跨学科合作。
要点
- 人iPSCD-gametes的临床引入需分临床试验前、中、后三阶段评估技术、伦理、法律与社会问题。
- 试验前评估人iPSCD-gametes安全性所需证据的收集将耗时且需用敏感研究材料开展平行实验。
- 人iPSCD-gametes质量不可避免且不可预见的变化可能进一步延缓其临床试验进程。
核心结论
- 作者认为,负责任地临床引入人iPSCD-gametes可能比预期耗时更长,强调与广泛利益相关方开展跨学科合作以做出周全选择的重要性。
研究设计与样本
- 本文为小型综述,按临床试验前(第1阶段)、临床试验中(第2阶段)和临床试验后(第3阶段)的顺序概述人iPSCD-gametes潜在临床引入涉及的问题。
主要发现
- 近期从小鼠多能干细胞生成SCD-gametes的进展使部分研究者预期人iPSCD-gametes将在二十年内临床引入。
- 第1阶段议题提示,收集临床前评估人iPSCD-gametes安全性所需证据将耗时且需用敏感研究材料开展平行实验。
- 第2阶段议题提示,人iPSCD-gametes通过各临床试验阶段可能需数年,其质量不可避免且不可预见的变化可能进一步延缓进程。
- 第3阶段议题提示,临床提供人iPSCD-gametes需解决问责与监测问题,其中部分可能难以用法律形式化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.
引用
- de Bruin IJ, Spaander MM, Harmsen S, et al. Stem cell-derived gametes: what to expect when expecting their clinical introduction. Hum Reprod. 2025. PMID: 40605085. doi:10.1093/humrep/deaf123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。